- Home
- CNTX vs IVVD Comparison
CNTX vs IVVD Comparison
Compare CNTX & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- IVVD
- Stock Information
- Founded
- CNTX 2015
- IVVD 2020
- Country
- CNTX United States
- IVVD United States
- Employees
- CNTX N/A
- IVVD N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- IVVD Health Care
- Exchange
- CNTX Nasdaq
- IVVD Nasdaq
- Market Cap
- CNTX 78.0M
- IVVD 69.0M
- IPO Year
- CNTX 2021
- IVVD 2021
- Fundamental
- Price
- CNTX $0.81
- IVVD $0.75
- Analyst Decision
- CNTX Strong Buy
- IVVD Strong Buy
- Analyst Count
- CNTX 5
- IVVD 3
- Target Price
- CNTX $5.50
- IVVD $5.85
- AVG Volume (30 Days)
- CNTX 193.2K
- IVVD 658.4K
- Earning Date
- CNTX 08-06-2025
- IVVD 08-13-2025
- Dividend Yield
- CNTX N/A
- IVVD N/A
- EPS Growth
- CNTX N/A
- IVVD N/A
- EPS
- CNTX N/A
- IVVD N/A
- Revenue
- CNTX N/A
- IVVD $36,688,000.00
- Revenue This Year
- CNTX N/A
- IVVD $345.16
- Revenue Next Year
- CNTX N/A
- IVVD $161.08
- P/E Ratio
- CNTX N/A
- IVVD N/A
- Revenue Growth
- CNTX N/A
- IVVD N/A
- 52 Week Low
- CNTX $0.49
- IVVD $0.35
- 52 Week High
- CNTX $2.75
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- CNTX 57.85
- IVVD 48.22
- Support Level
- CNTX $0.82
- IVVD $0.78
- Resistance Level
- CNTX $0.88
- IVVD $0.86
- Average True Range (ATR)
- CNTX 0.07
- IVVD 0.05
- MACD
- CNTX 0.00
- IVVD 0.01
- Stochastic Oscillator
- CNTX 42.87
- IVVD 46.30
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.